On October 28, 2020, after 11 years of listing on HNX (Hanoi Stock Exchange with 13.5 million shares, Ben Tre Pharmaceutical Joint Stock Company (DBT) will move to list on HOSE (Ho Chi Minh Stock Exchange). Ho Chi Minh Stock Exchange).
Strengths of DBT
With a long history of formation and development, DBT always captures the advantages of the industry. Strongly developed from only one pharmaceutical distributor in the province, after being equitized and going through many stages of restructuring, DBT's distribution network has now been covering the whole country. The amount of goods is diversified from import to production of the company.
In the last 5 years, implementing the production strategy as the foundation for promoting drug distribution and quality control, DBT has expanded production in the field of traditional medicines and biological products. Currently, DBT holds 82.15% of the charter capital of Yen Bai Pharmaceutical Joint Stock Company (Ypharco).
Cam Xuyen Huong is currently a prominent product of Ypharco traditional medicine enterprise for more than 25 years. Belonging to the group of products to treat colds and flu, produced with a GMP-WHO standard Oriental medicine factory.
Currently, DBT expands its product portfolio to biological products and holds a 51% ownership rate in Nha Trang Vaccine and Biological Products Joint Stock Company (Biopharco). This enterprise is famous for its EnteroGolds and EnteroGran biological product lines, which are applied to transfer production and business technology of biological vaccines to users. The factory is GMP-WHO certified and is focusing on high quality product lines.
In addition, DBT will continue to expand the field of pharmaceutical production, focusing on modern medicines that meet EU standards and expand imports with high quality products from Europe.
DBT has always been a reliable partner of leading pharmaceutical companies in the world such as Richter, Sanavita, Egis, etc. The direction of the Company is to continue to expand products from developed markets.
"Good medicine - Sustainable development" is the motto of the Company, which wants to bring drugs to consumers at a reasonable price. The company is distributing more than 250 medicinal products, aiming to distribute more drugs for women and children.
DBT applies specific ERP management methods for pharmaceutical distribution by business channels. The company continues to improve its distribution system to optimize the time it takes to deliver drugs to consumers.
General Director Mr. Pham Thu Trieu shared that “The company is capable of participating in national bidding. We focus on developing production and in-house production, controlling the best and most effective quality, and ensuring reasonable drug prices for the community.” The company is promoting the development of a high-value product chain with specialized products, including product groups from traditional medicines to pharmaceutical chemicals, vaccines and biological products.
Opportunities for DBT stock
DBT listed 3 million shares on HNX on October 30, 2009, so far the shares have increased 4.5 times. The move to list on HOSE on October 28 is a special milestone for DBT, and at the same time marks the maturity in all aspects, both in terms of production, business and administration activities, helping to improve trademark of the Company.
In the past 4 years, DBT's business has been relatively stable with a profit after tax of VND 25-30 billion/year and a stable dividend of 8 - 15%.
DBT sets a target in the next quarter to achieve an average revenue of 10%/year, average profit of 15%/year and dividend of about 10%/year.